What is BioLamina?
BioLamina is a pioneering Swedish biotechnology company dedicated to the development and provision of full-length human recombinant laminins. These advanced biomaterials serve as a biologically relevant matrix for cell culture applications, significantly enhancing cell functionality and supporting both 2D and 3D cell culture systems. The company's offerings are meticulously designed to meet stringent regulatory requirements, ensuring clinical compliance and fostering reproducible research outcomes. By focusing on the improvement of cell performance and differentiation, BioLamina is strategically positioned to drive advancements in the critical fields of cell therapy and regenerative medicine.
How much funding has BioLamina raised?
BioLamina has raised a total of $18.2M across 1 funding round:
Other Financing Round
$18.2M
Other Financing Round (2023): $18.2M with participation from Lauxera Capital Partners
Key Investors in BioLamina
Lauxera Capital Partners
Lauxera Capital Partners is an independent investment fund specializing in growth companies within the Healthtech sector. They focus on early profitability stage Healthtech businesses, aiming to enhance efficiency and reduce costs through strategic investments and partnerships.
What's next for BioLamina?
The recent major strategic investment signifies a pivotal moment for BioLamina, indicating strong investor confidence in its innovative cell culture solutions and its potential to impact regenerative medicine. This capital infusion is expected to accelerate the company's research and development initiatives, potentially expanding its product portfolio and market reach. With a clear focus on clinical compliance and reproducible results, BioLamina is well-equipped to capitalize on the growing demand for high-quality cell culture matrices, further solidifying its role in facilitating breakthroughs in therapeutic applications and scientific research.
See full BioLamina company page
